05-04-2012: Ablynx noted that a paper on a novel tetrameric Nanobody® agonist (TAS266) targeting Death Receptor 5 (DR5), a key receptor target on cancer cells across a number of tumour types, was presented at the American Association for Cancer Research Annual Meeting in Chicago by Novartis. The ability of TAS266 to efficiently 'cross-link' DR5 receptor targets, apparently not achievable with conventional monoclonal antibodies, results in the controlled death of cancer cells.
The abstract summarizes the results of the pre-clinical in vitro and in vivo studies of a tetravalent anti-DR5 Nanobody in an oncology setting. TAS266 was shown to elicit sustained tumour regressions in multiple tumour xenograft models, including a patient-derived primary pancreatic tumour model that is insensitive to a conventional anti-DR5 agonist antibody. Also, compared to some of the other therapeutic agonists against DR5 that have been developed and that have been clinically evaluated, TAS266 proved to be up to 1000-fold more potent in tumour cell death assays.
In view of this, the authors of the abstract conclude that "TAS266 has the potential for superior clinical activity in settings insensitive to the conventional therapeutic approaches to DR5."
Ablynx and Algeta ASA announce a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta’s proprietary thorium-227 alpha-pharmaceutical payload with Nanobodies® generated using Ablynx’s proprietary technology platform.Under the terms of the coll ... more
Ablynx announced that Dr Roger Perlmutter and Dr Russell G. Greig will be proposed as Independent Non-Executive Directors at the Company's forthcoming Extraordinary General Meeting of its shareholders at the beginning of November 2012.Dr Perlmutter was Executive Vice President, Research an ... more
Ablynx announced that it has achieved positive results from a Phase I study with the first ever inhaled Nanobody, ALX-0171, a trivalent molecule which has been specifically designed by Ablynx for direct lung delivery, via a nebuliser, to treat respiratory syncytial virus (RSV) infections.Th ... more
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currentl ... more
Oxford BioMedica plc announced that it has signed an agreement with Novartis to manufacture clinical grade material utilising Oxford BioMedica’s LentiVector® gene delivery technology. Under the terms of the agreement, Oxford BioMedica will also provide certain process development services ... more
Evotec AG announced that it has received a pre-clinical milestone from its Drug Discovery Collaboration with Novartis. No financial details were given.
Under the terms of the agreement, Evotec is responsible for progressing the program up to pre-clinical development and Novartis will then h ... more
Novartis and the University of Pennsylvania (Penn) announced an exclusive global collaboration to research, develop and commercialize targeted chimeric antigen receptor (CAR) immunotherapies for the treatment of cancers. In addition, the parties will jointly establish a new research and dev ... more
We focus on the well-being of companion animals and the health and productivity of farm animals. Our extensive product range provides solutions for the prevention and treatment of various widespread animal diseases and parasite infestations. The majority of these products are available by p ... more